Pharma & Biotech - Page 9

Replimune (REPL) secured a landmark accelerated approval for its cancer therapy Tudriqev last month, following a pivotal intervention from senior FDA leadership. Two votes of confidence from officials at the FDA’s Office

Amgen (AMGN) has unveiled compelling new data showing its cholesterol-lowering drug Repatha significantly reduces the risk of death in high-risk cardiovascular patients. The findings, announced on 31 August 2026, come from a

The pharmaceutical distribution industry is closely watching the development of a national licensure standard that could reshape compliance requirements for wholesalers and third-party logistics providers. Kala Shankle, JD, Vice President of Regulatory

Novartis has announced plans to cut approximately 130 jobs in Switzerland as it restructures laboratory and production activities at its Kleinbasel site in Basel. The Swiss pharmaceutical giant confirmed it will transfer

The pharmaceutical industry has entered a planning and preparation phase following the FDA’s publication of its final rule on 12-digit National Drug Codes. Liberty Dewey, manager of DSCSA at Cardinal Health, describes

The US health research agency ARPA-H has awarded up to $125 million across five teams to build automated systems capable of producing personalised RNA medicines in under a week. The funding forms

Independent Pharmacy Cooperative has completed its acquisition of USave Pharmacy Group, with the deal taking effect on September 1 of this year. The two purchasing organisations have worked in close collaboration for

Pharmaceutical advertising during NFL regular season games proved dramatically more effective than standard broadcast placements during the 2025-26 season, according to TV measurement firm EDO. Pharma ads airing during NFL regular season

Genentech growth marketing leader Tiffany William has built a reputation for applying lessons from the mobile gaming world to pharmaceutical marketing strategy. William, based in the San Francisco Bay Area, leads growth

The U.S. Food and Drug Administration has issued an untitled letter to Alar Pharmaceuticals over misleading promotional claims about an investigational ketamine treatment. The FDA’s Office of Prescription Drug Promotion issued the